Form 4: Vertex Pharmaceuticals EVP and CMO, Carmen Bozic, Reports Stock Disposal
SEC Form 4 Filing
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reports the disposal of 2,142 shares of common stock to cover tax obligations.
Summary
- On February 10, 2025, Carmen Bozic, the EVP and CMO of Vertex Pharmaceuticals, disposed of 2,142 shares of common stock.
- The transaction was executed at a price of $467.98 per share.
- Following the transaction, Bozic directly owns 37,307 shares of Vertex Pharmaceuticals common stock.
- The disposal was related to tax obligations.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like executives and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors to gain insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of stock disposal transaction. |
| 02/12/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.